Selank + Semax Information & Coordination for Licensed U.S. Clinics
Selank and Semax are peptide substances that have appeared in research literature and in discussions surrounding pharmacy compounding.
FDA materials reviewed for this page do not identify an FDA-approved Selank + Semax combination drug product. The two substances have separate regulatory histories and should be evaluated separately.
FDA currently identifies safety concerns involving Selank acetate (TP-7), including potential immunogenicity associated with aggregation and peptide-related impurities. FDA separately evaluated Semax free base and Semax acetate in 2026 and states that neither is a component of an FDA-approved drug.
Phoenix Meds Inc. provides licensed healthcare organizations with administrative support around credentials, documentation, and publicly available regulatory information.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About Selank and Semax
Selank and Semax have separate regulatory histories and should not be treated as though the combination has one established FDA status.
For Selank acetate, FDA currently notes potential safety concerns involving aggregation, peptide-related impurities, and immunogenicity, while also stating that important human-safety information is lacking.
For Semax, FDA evaluated Semax free base and Semax acetate in 2026. Neither has an applicable USP/NF drug-substance monograph and neither is a component of an FDA-approved drug. FDA concluded that the available criteria weighed against placing either on the 503A Bulks List.
Phoenix does not promote Selank, Semax, or their combination for anxiety, cognitive enhancement, memory, focus, neuroprotection, neurological recovery, mood, immune modulation, or other treatment outcomes.
Separate Regulatory Considerations
Selank
FDA removed Selank acetate (TP-7) from Category 2 in September 2024 after receiving information that the nominator had intended to nominate a different bulk drug substance. That removal should not be interpreted as FDA approval or placement of Selank on the 503A Bulks List.
FDA’s current safety information continues to identify potential concerns involving compounded Selank acetate.
Semax
Semax free base and Semax acetate were considered at FDA’s July 24, 2026 Pharmacy Compounding Advisory Committee meeting.
FDA reviewed proposed uses involving cerebral ischemia, migraine, and trigeminal neuralgia and concluded that the available evaluation criteria weighed against placing the substances on the 503A Bulks List.
Advisory-committee recommendations are non-binding, and FDA states that it does not make a final determination until the advisory process and its reviews are complete.
Why the Combination Should Be Reviewed Carefully
Combining the names “Selank” and “Semax” on one product page does not create a separate FDA approval, established clinical indication, or compounding status.
Each substance needs to be evaluated according to the regulatory information applicable to that substance.
Product naming also matters. FDA has specifically identified inconsistent naming and characterization issues for Semax-related bulk drug substances.
Phoenix can help organize publicly available records and documentation so clinics can identify issues that require further professional review.
How Phoenix Meds Supports Licensed Clinics
Our role is administrative.
Licensed healthcare organizations may use Phoenix for help organizing professional credentials, reviewing documentation, checking publicly available licensing and regulatory information, and identifying gaps or inconsistencies that need further review.
We help make the administrative record easier to understand without making clinical decisions or determining that a particular preparation is legally eligible for compounding.
Our review is not FDA approval, pharmacy accreditation, a treatment recommendation, or a legal opinion.
Safety and Documentation Considerations
FDA’s current compounding-safety materials separately identify concerns involving Selank acetate (TP-7) and Semax (heptapeptide).
For Selank acetate, FDA cites potential immunogenicity associated with aggregation and peptide-related impurities and says important human-safety information is lacking. For Semax, FDA has also identified potential immunogenicity and peptide-related impurity concerns.
Phoenix does not manufacture, test, compound, dispense, ship, or take custody of Selank or Semax. We also do not certify purity, potency, sterility, authenticity, safety, or clinical suitability.
Selank + Semax Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations may contact Phoenix Meds Inc. regarding credential review, documentation, and publicly available regulatory information concerning a Selank- or Semax-related professional inquiry. An administrative inquiry is not a medication order and does not establish FDA approval, compounding eligibility, product availability, or clinical appropriateness.
Clinic Verification
Documentation Review
Licensed Parties
Prescribing, compounding, dispensing, distribution, storage, shipping, and other regulated medication activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Are Selank and Semax FDA approved?
Phoenix does not present either Selank or Semax as an FDA-approved drug product. FDA states that Semax free base and Semax acetate are not components of FDA-approved drugs, and FDA has previously addressed compounded Selank in its enforcement and compounding materials.
Is Selank + Semax an FDA-approved combination?
FDA materials reviewed for this page do not identify an FDA-approved Selank + Semax combination drug product.
Does combining Selank and Semax change their regulatory status?
No FDA material reviewed for this page establishes a separate approval or compounding status simply because the substances are discussed together.
Does Phoenix Meds compound or dispense Selank + Semax?
No. Phoenix does not compound, manufacture, dispense, test, ship, or take custody of these substances.
What can Phoenix Meds help clinics with?
Our work is administrative and may include credential review, document organization, publicly available regulatory information, and professional communication.
Does Phoenix Meds provide dosing or treatment protocols?
No. We do not provide patient-specific dosing, protocols, or clinical recommendations.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not present Selank, Semax, or their combination as FDA-approved treatments and does not establish that a particular compounding or distribution pathway is available or permitted.
Regulatory References
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
- 503A Categories Update — September 2024
- July 23–24, 2026 Pharmacy Compounding Advisory Committee
- Semax-Related Bulk Drug Substances — FDA Briefing Document
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act